Regeneron (REGN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Regeneron Pharma (REGN) Price Target Raised to $410 at RBC
November 4, 2014 3:28 PM ESTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00). Comments follow Q3 results. Analyst Adnan Butt said he was a buyer of pullbacks.
"While ramp from DME did not materialize, the... More
Regeneron Pharma (REGN) Price Target Raised to $455 at Deutsche Bank
November 4, 2014 1:39 PM ESTDeutsche Bank reiterated a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $455.00 (from $425.00). The change follows Q3 results. Analyst Robyn Karnauskas sees major upside in the stock next year.
"Eylea US sales for 3Q missed expectations at... More
